STOCK TITAN

IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

IGC Pharma (IGC) completed dosing in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia. All 170 participants completed the six-week treatment phase, and all required treatment-period visits and assessments are complete. The trial randomized 170 participants, exceeding its enrollment target of 146, at sites in the United States and Canada.

The placebo-controlled trial's primary endpoint is change in agitation from baseline to Week 6, measured with the Cohen-Mansfield Agitation Inventory. Final data checks are underway before the database is locked, treatment assignments are revealed and the results are independently analyzed. IGC Pharma expects topline results in December 2026 or January 2027, subject to clinical trial and data-management uncertainties.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointPhase 2 CALMA treatment is complete for all 170 participants, including required visits and assessments
  • Minor pointCALMA enrollment exceeded the original target of 146, with 170 participants randomized
  • Minor point. Forward-looking: it has not happened yet and may not happen.Topline results are expected in December 2026 or January 2027, subject to clinical trial and data-management uncertainties

Negative

  • Minor pointFinal data checks are still underway; database lock, unblinding and independent analysis remain pending

Key Figures

Participants: 170 participants Original enrollment target: 146 participants Treatment duration: Six weeks +1 more
Participants
170 participants
Randomized in CALMA across U.S. and Canadian clinical sites
Original enrollment target
146 participants
CALMA enrollment exceeded this target
Treatment duration
Six weeks
CALMA treatment phase
Topline results timing
December 2026/January 2027 timeframe
Company anticipates reporting; subject to clinical trial and data-management uncertainties

Previous Clinical trial Reports

1 past event · Latest: Sep 28
Same Type 1 event
  1. Sep 28

    CALMA enrollment

    24h Move
    -3.0%

    Completed enrollment of 168 participants; final dosing and Q4 topline results remained ahead.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

placebo-controlled, database lock, cohen-mansfield agitation inventory (cmai), statistical analysis plan
4 terms
placebo-controlled medical
"randomized, double-blind, placebo-controlled Phase 2 clinical trial"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
database lock technical
"ahead of database lock, unblinding, and independent statistical analysis"
A database lock is the point in a clinical trial when the collected study data are finalized and no further changes or corrections are allowed, so analysts can run the official statistical tests. For investors this matters because it usually precedes public results or regulatory filings—think of it like sealing and signing off an exam before grading: once locked, the timing and content of the readout become clearer and uncertainty about last-minute data edits is reduced.
cohen-mansfield agitation inventory (cmai) medical
"using the Cohen-Mansfield Agitation Inventory (CMAI)"
A caregiver- or clinician-completed questionnaire that scores the frequency and severity of agitated behaviors in older adults, most often those with dementia. Think of it as a behavioral thermometer that turns observations—like restlessness, aggression, or repetitive actions—into a single number; investors track those scores because they appear in clinical studies and care assessments, and meaningful score changes can affect a treatment’s perceived effectiveness, regulatory outcomes, reimbursement, and market potential.
statistical analysis plan technical
"under the study's statistical analysis plan"
A statistical analysis plan is a detailed written blueprint that explains exactly how study data will be measured, compared and reported, including which outcomes will be examined, which calculations will be used, and how missing or messy data will be handled. For investors it matters because a clear, pre‑set plan reduces the risk of biased or surprising results—think of it as a recipe that ensures reported findings are reproducible and trustworthy for judging a drug or product’s prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

POTOMAC, MD / ACCESS Newswire / November 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease, today announced the completion of the six-week treatment phase of CALMA for all its 170 participants.

The final participant has completed dosing, and all required treatment-period visits and assessments are complete. The trial randomized 170 participants with agitation in Alzheimer's dementia across clinical sites in the United States and Canada, exceeding its original enrollment target of 146 participants.

With the treatment phase complete, CALMA is advancing through final data verification, reconciliation, and quality-control activities ahead of database lock, unblinding, and independent statistical analysis.

"Completing treatment and all required treatment-period assessments is a major milestone for CALMA," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Our focus now shifts to preparing the data for a rigorous, independent analysis. For families living with Alzheimer's dementia, agitation can be among the most difficult symptoms to manage. We are grateful to the patients, caregivers and clinical teams who made this study possible, and we look forward to learning what CALMA tells us about IGC-AD1."

Agitation in Alzheimer's dementia can involve restlessness, pacing, verbal outbursts, and physical aggression. These symptoms can place significant burdens on patients and caregivers and contribute to the need for residential care.

CALMA is a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating IGC-AD1, an investigational oral liquid medication, over six weeks of treatment. The primary endpoint measures change in agitation from baseline to Week 6 using the Cohen-Mansfield Agitation Inventory (CMAI). Additional assessments include cognition, caregiver burden, safety, tolerability, and biomarkers.

Next Steps

IGC Pharma is completing the remaining data-management and quality-control activities required for database lock. Following database lock, treatment assignments will be unblinded, and the results will undergo independent statistical analysis under the study's statistical analysis plan. The Company anticipates reporting topline results during the December 2026/January 2027 timeframe, subject to clinical trial and data-management uncertainties.

About IGC Pharma, Inc. (dba IGC)

IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease and AI-enabled technologies supporting drug discovery, clinical research, cognitive risk assessment and brain-health monitoring. Its lead therapeutic candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA clinical trial for agitation in Alzheimer's dementia. The Company's AI portfolio includes MINT-AD, PRISM and aha, its Agentic Harmonization Assistant, which are being developed to support Alzheimer's research and potential healthcare applications.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated timing of database lock, unblinding, independent statistical analysis, the reporting of topline results timeframe, and the future development of IGC-AD1. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results, events, and timelines to differ materially. Such risks and uncertainties include delays or changes in data verification, reconciliation, quality-control activities, database lock, unblinding, the availability and scheduling of independent statisticians, and statistical analysis; the possibility that trial results may differ from expectations or may not demonstrate the safety, tolerability, or efficacy of IGC-AD1; and clinical, operational, regulatory, and financing risks described in IGC Pharma's filings with the U.S. Securities and Exchange Commission. The anticipated timing is an estimate and may change as these activities progress. IGC-AD1 is investigational and has not been approved for any indication. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contacts:

General: Andres Sanchez, info@igcpharma.com, + 1-301-983-0998
Media: Kiran Mukunda, kmukunda@igcpharma.com

SOURCE: IGC Pharma, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does IGC Pharma expect Phase 2 CALMA results for IGC-AD1?

IGC Pharma expects topline CALMA results in December 2026 or January 2027, subject to clinical trial and data-management uncertainties.

What did IGC Pharma's Phase 2 CALMA trial assess besides agitation?

CALMA also assessed cognition, caregiver burden, safety, tolerability and biomarkers.

Keep reading